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Abstract
MicroRNAs (miRNAs) are small non-coding RNAs that function as post-transcriptional regu-
lators of gene expression and are dysregulated in cancer. Studies of miRNAs to explore
their potential as diagnostic and prognostic markers are of great scientific interest. Here, we
investigate the functional properties and expression of the miR-143/145 cluster in breast
cancer (BC) in vitro and in vivo. The ER positive MCF7, the HER2 positive SK-BR-3, and
the triple negative cell line MDA-MB-231 were used to assess cell proliferation and cell inva-
sion. Expression of miRNA in 108 breast cancers in the Norwegian Women and Cancer
Study and 44 benign tissue controls were analyzed by microarray and validated by RT-
PCR. Further, in situ hybridization (ISH) was used to study the cellular and subcellular distri-
bution of the miRNAs. In vitro, miR-143 promoted proliferation of MCF7 and MDA-MB-231
cells, whereas miR-145 and the cotransfection of both miRNAs inhibited proliferation in all
three cell lines. The cells’ invasive capacity was reduced after transfection and cotransfec-
tion of the miRNAs. In line with the tumor suppressive functions in vitro, the expression of
miR-143 and miR-145 was lower in malignant compared to benign breast tissue, and lower
in the more aggressive tumors with higher tumor grade, loss of ER and the basal-like pheno-
type. ISH revealed miR-143 to be cytoplasmatic and predominantly expressed in luminal
cells in benign tissue, whilst miR-145 was nuclear and with strong staining in myoepithelial
cells. Both miRNAs were present in malignant epithelial cells and stromal fibroblasts in BC.
This study demonstrates that miR-143 and -145 have functional properties and expression
patterns typical for tumor suppressors, but the function is influenced by cellular factors such
as cell type and miRNA cotransfection. Further, the nuclear functions of miR-145 should be
explored for a more complete understanding of the complexity of miRNA regulation and
function in BC.
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Introduction
Breast cancer (BC) is the most common cancer diagnosed in women [1]. Clinical classification of
BC is done by assessing histological type, grade, stage and receptor status where tumors can be
categorized as estrogen receptor positive (ER+), and/or human epidermal growth factor receptor
2 positive (HER2+), or triple negative (TN) [2]. The ER+ BCs constitute nearly 70% of all cases
[3], and this group has extended therapeutic options, compared to the HER2+ and TN BCs.
Based on gene expression profiles, the ER+ tumors can be divided into the molecular sub-
types luminal A and luminal B, where the luminal B subtype has a worse prognosis due to a
higher proliferation rate and/or HER2 positivity [4, 5]. The HER2+ BCs are commonly associ-
ated with ductal carcinoma in situ (DCIS) and in general have a moderate to poor prognosis
[4, 5]. The TN BCs constitute a heterogeneous group of tumors, where the majority of cases
are presented as basal-like BCs [6]. The TN BCs typically include the most aggressive breast
carcinomas, where the majority of cancer related death occur within five years from time of
diagnosis [5, 6]. Molecular profiles are used to guide treatment. However, when comparing
individual cases, BCs have highly heterogeneous gene expression contributing to the chal-
lenges of treating BC patients [7]. Further, BC is still one of the leading causes of cancer deaths
in women [1], underlining the need for improved prognostic and predictive biomarkers for
early detection, identification and stratification of the most aggressive tumors, and more tar-
geted treatment.
MicroRNAs (miRNAs) constitute a group of small non-coding endogenous RNAs with a
typical length of 18–22 nucleotides. Mature miRNAs bind to the complementary or semi com-
plementary 3’untranslated region (3’-UTR) of mRNAs, resulting in negative regulation of pro-
tein translation [8]. The downregulation of protein synthesis can be a result of miRNA
induced mRNA degradation, mRNA destabilization, or mRNA silencing [9]. The nature of the
negative regulation is dependent upon the degree of complementarity between the mature
miRNA and the 3’-UTR target [9]. Due to the highly pleiotropic nature of miRNAs, it is pre-
dicted that more than 60% of all human protein coding genes are influenced by miRNAs, and
their dysregulation is a universal event for virtually all types of malignancies, as they have a
profound influence on most cellular processes [10–12]. Expression profiles of miRNA have
been shown to categorize various cancers more accurately than mRNA [13], and miRNAs can
be considered novel regulators in the hallmarks of human cancers [14]. Combined with miR-
NAs’ biochemical properties that make them suitable as biomarkers, it is of great scientific
interest to investigate and characterize individual miRNAs, their expression, and their func-
tional roles in BC and BC subtypes.
MiR-143 and miR-145 constitute a miRNA cluster and appear to have tumor suppressor
functions in a variety of organ systems, both as individual miRNAs and as a cluster [15–24].
This study evaluates the miR-143 and miR-145 expression profile in an unselected cohort of
BC within the Norwegian Women and Cancer Study (NOWAC) postgenome cohort [25].
Samples were stratified in subgroups based on molecular subtype, receptor status, tumor grade
and lymph node status. In addition, through a series of in vitro experiments, including assays
for cell proliferation and cell invasion, the functionality of miR-143 and miR-145 was studied
in BC cell lines analogous to the major subtypes of breast cancer; ER+, HER2+ and TN BC.
Materials and methods
Ethics statement
The study of miRNA expression in BC samples from the NOWAC postgenome cohort and
benign breast tissue has been approved by the regional ethical committee of North Norway
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(REKnord 2010/1931, 2013/2271). The Data Inspectorate has also approved the storing of rele-
vant, not identifiable data and the linkage to national registries. In addition, ethical aspects
have been considered within the project to ensure the most efficient and accurate use of the
material collected and data generated, in accordance with national and international guide-
lines and laws.
Functional studies
The potential function of miR-143 and miR-145 in tumorigenesis was investigated by a series
of in vitro experiments. The experiments were performed by introducing miR-143 mimic or
miR-145 mimic, alone or in combination, alongside a miRNA negative control into various
BC cell lines. In this study, cell proliferation and cell invasion were assessed.
Cell cultures. The functions of miR-143 and miR-145 were evaluated in three different
BC cell lines. These included the ER+ MCF7 (ATCC 1 HTB-22™), the HER2+ SK-BR-3
(ATCC1 HTB-30™), and the TN BC cell line MDA-MB-231 (ATCC1 CRM-HTB-26™). All
cell lines, except MCF7, were cultured in RPMI-1640 media (cat.# R8758, Sigma-Aldrich,
St. Louis, USA) supplemented with 10% fetal bovine serum (cat.# S0415, Biochrom, Berlin,
Germany). MCF7 were cultured in DMEM (cat.# D5796, Sigma-Aldrich, St. Louis, USA) with
the same supplements as the previously described cell lines. All cell lines were incubated at
37˚C in humidified atmosphere with 5% CO2. Total RNA from the non-cancerous breast cell
line MCF-10A was a kind gift from the research group of professor E. Mortensen, RNA and
molecular pathology (RAMP) research group, UiT—The Arctic University of Norway,
Tromsø, Norway.
Cell transfection. All cell lines were transiently transfected with 100 nM hsa-miR-143-3p
Pre-miR™ miRNA Precursor (cat.# PM10883, Thermo Fisher Scientific, USA) and/or 100 nM
hsa-miR-145-5p Pre-miR™ miRNA Precursor (cat.# PM11480, Thermo Fisher Scientific,
USA), alongside the Cy3™ Dye-Labeled Pre-miR Negative Control #1 (cat.# AM17120, Thermo
Fisher Scientific, USA). The transfection was performed by using 6 μl/mL of the Lipofecta-
mine1 RNAiMAX transfection reagent (cat.# 13778075, Thermo Fisher Scientific, USA).
Transfected Cy3™ Dye-Labeled Pre-miR Negative Control emits fluorescent light when
exposed to UV-light, and the transfection efficiency was determined using a fluorescence
microscope. The transfection efficiency was typically as high as 80–95%.
Total RNA isolation. Total RNA was isolated from cell lines using the miRNeasy Mini Kit
(cat.# 217004, Qiagen, Hilden, Germany) according to the manufacturer’s protocol. In short,
cells were lysed in 700 μl QIAzol Lysis Reagent before homogenization and 5 minutes incuba-
tion at room temperature. 140 μl chloroform were added, and the samples were shaken before
incubation at room temperature for 3 minutes. Samples were centrifuged for 15 minutes at
12000 g at 4˚C, and the upper aqueous phase was transferred and mixed thoroughly with 100%
ethanol. The samples were transferred into the RNeasy1 Mini column and washed in several
steps before elution with 50 μl ddH2O. Isolated total RNA samples were stored at -70˚C.
cDNA synthesis. First strand cDNA synthesis was performed using the miScript II RT Kit
(cat.# 218160, Qiagen, Hilden, Germany) according to the manufacturer’s protocol. Briefly,
100 ng of total RNA was mixed with 4 μl 5x miScript HiSpec Buffer, 2 μl 10x Nucleics Mix, 2 μl
miScript Reverse Transcriptase Mix, and RNase-free water to a total volume of 20 μl. Samples
were incubated for 60 minutes at 37˚C, and subsequently incubated for 5 minutes at 95˚C to
inactivate enzymes. Finally, samples were diluted up to a total volume of 200 μl in RNase-free
water and stored at -20˚C.
RT-PCR. Endogenous levels of miR-143 and miR-145 in the selected cell lines were quan-
tified relative to the stably expressed reference snRNA RNU6 using real-time PCR and the
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miScript SYBR1 Green PCR Kit (cat.# 218073, Qiagen, Hilden, Germany). Primers used were
miScript Primer Assays Hs_miR-143_1 miScript Primer Assay (cat.# MS00003514, Qiagen,
Hilden, Germany), Hs_miR-145_1 miScript Primer Assay (cat.# MS00003528, Qiagen, Hilden,
Germany) and Hs_RNU6-2_11 miScript Primer Assay (cat.# MS00033740, Qiagen, Hilden,
Germany), according to the manufacturer’s protocol. Briefly, a total volume of 25 μl/well in a
96-well plate included 1 μl cDNA mixed with 12.5 μl 2x QuantiTect SYBR Green PCR Master
Mix, 2.5 μl 10x miScript Universal Primer, 2.5 μl 10x miScript Primer Assay, and 6.5 μl RNase-
free Water. The plate was sealed and centrifuged for 1 minute at 1000 g before it was placed in
a 7300 Real-Time PCR System (Thermo Fisher Scientific, Waltham, Massachusetts, USA).
Each sample was analyzed in quadruplicates, and three independent experiments were
performed.
Proliferation assay. The BC cell lines’ ability to proliferate after transfection was evalu-
ated using the real-time cell analyzer system xCelligence, RTCA DP (cat#05469759001, ACEA
Biosciences, San Diego, USA) fitted with the E-plate 16 (cat#05469830001, ACEA Biosciences,
San Diego, USA). Prior to analysis on the xCelligence platform, cell lines were trypsinized
until detached, resuspended in complete growth media, and counted. Initial titration experi-
ments estimated approximately 8000 cells per well to be optimal. In accordance with the
manufacturer’s protocol, cells were seeded in quadruplicates into an E-plate after baseline
measurements. The E-plate containing cells was incubated for 30 minutes at room tempera-
ture before positioned in the RTCA DP instrument, which was located in an incubator pre-
serving the same conditions as used for routine cultivation of cell lines. The instrument
denotes the cellular growth rate as ‘Cell Index’, which is an arbitrary unit reflecting the cell-
sensor impedance. The cell index was recorded by the instrument every 30 minutes. Growth
curves were calculated with the RTCA software version 1.2.1 (ACEA Biosciences, San Diego,
USA). A minimum of three independent experiments were performed for each cell line.
Invasion assay. The cell lines invasiveness after transfection was tested using the CytoSe-
lectTM 96-well Cell Invasion Assay, Basement membrane (cat.# CBA-112, Cell Biolabs, San
Diego, USA) according to the manufacturer’s protocol. Briefly, 50000 pretransfected and
serum starved cells were seeded in the upper chamber of a modified Boyden chamber. The
chamber was coated with a basement membrane consisting of a protein matrix isolated from
Engelbreth-Holm-Swarm tumor cells, and the cells were allowed to invade for 24 h towards
the bottom chamber containing media+10% FBS. Cancer cells able to invade the basement
membrane and pass through the porous membrane to the bottom side of the membrane were
lysed, stained, and fluorescence was measured at 480/520 nm using the CLARIOstar1 micro-
plate reader (BMG LABTECH, Ortenberg, Germany). All experiments were performed in qua-
druplicates, and a minimum of three independent experiments were performed for each cell
line.
Patient material and tumor classification
The patient samples were collected from the NOWAC postgenome cohort [25]. The NOWAC
participants included in this study were diagnosed with breast cancer at the Department of
Pathology at the University Hospital of North Norway in Tromsø, or the Nordland Hospital in
Bodø in the years 2004–2010. Archived formalin-fixed paraffin-embedded (FFPE) tissue
blocks, and hematoxylin and eosin stained slides were collected. Histological grading of
tumors was based on the criteria modified by Elston and Ellis [26] and immunohistochemical
(IHC) analyses of ER, progesterone receptor (PR) and HER2 were done on needle biopsies as
part of routine diagnostics. The cut-off value for ER positivity was 1%, for PR 10% and a
HER2 score of 3+ was considered positive, a score of 0–1+ negative whereas a score of 2+ lead
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to silver in situ hybridization (SISH) where HER2 was considered negative if HER2/chromo-
some 17-ratio was< 2. IHC staining for the proliferation marker Ki67 was done on slides
from the primary surgery, and the expression evaluated in at least 500 tumor cells in the most
proliferative areas of the tumor and the result reported as a percentage of positive tumor cells.
Subtyping of the tumors according to molecular profile were based on the surrogate markers
ER, PR, HER2 and Ki67 according to recommendations by the St Gallen International Expert
Consensus and previous publications [27, 28]. The subtyping was performed as follows: lumi-
nal A (ER+ and/or PR+, HER2- and Ki67 30%), luminal B (ER+ and/or PR+, HER2- and
Ki67> 30% or ER+ and/or PR+ and HER2+), HER2 positive (ER- and PR- and HER2+) and
basal-like (ER-, PR- and HER2-). Histopathological data were collected from the original
pathology reports, and reevaluated and completed according to updated criteria by a breast
pathologist (L.M.). As benign tissue controls, FFPE tissue cores from 44 breast reduction sur-
gery specimens were included in the study.
miRNA microarray
Total RNA was extracted from FFPE tissue cores from both malignant and benign breast tissue
using the RecoverAll Total Nucleic Acid Isolation kit (Life Technologies, Grand Island, NY,
USA) following the manufacturer’s instructions. RNA quality and quantity was assessed using
the NanoDrop 1000 spectrophotometer (Thermo Fisher Scientific, Wilmington, DE). Micro-
array hybridization and analyses were performed as a bought service by Exiqon (Vedbaek,
Denmark). In short, the miRCURY LNATM microRNA Hi-Power Labeling Kit (Exiqon) was
used to label 250 ng total RNA from samples and reference with Hy3TM and Hy5TM, respec-
tively. The Hy5TM -labeled reference RNA contained an equal aliquot of all RNA species
included in the study. Labeled samples and reference RNA were mixed before hybridization to
the 7th generation miRCURY LNA microRNA array (Exiqon), using a Tecan HS4800 hybrid-
ization station (Tecan, Austria). The microarray contained capture probes for miRNAs in
human, mouse and rat as annotated in miRBASE version 19.0. The slides were scanned on the
Agilent G2565BA Microarray Scanner System (Agilent technologies Inc., USA) and the Ima-
Gene 9.0 software (BioDiscovery Inc., USA) was used for image analysis. The quantified sig-
nals were background corrected and normalized using quantile normalization method and
detection threshold set as 1.2 times the 25th percentile of the overall signal intensity of the indi-
vidual slides.
Validation of microarray and quantification of miRNAs by RT-qPCR
Microarray miRNA analyses were validated using RT-qPCR. 40 tumor samples representing
the four major molecular subtypes of cancer included in the study, and 20 of the benign breast
tissue controls were included in the PCR validation done by Exiqon. In short, RNA was
extracted from FFPE tissue cores using the Qiagen miRNeasy FFPE kit according to the manu-
facturer’s instructions (Qiagen, Hilden, Germany). 10 ng RNA was reverse transcriped using
the miRCURY LNA Universal RT microRNA PCR, Polyadenylation and cDNA synthesis kit
(Exiqon) and PCR-reactions performed on 100 x diluted cDNA using ExiLENT SYBR Green
master mix. The amplification was done in a Light Cycler 480 Real-Time PCR System (Roche)
in 384 well plates. All reverse transcription reactions were done in duplicates. Based on stable
expression across the data set, the most suitable reference miRNAs were evaluated by Exiqon
using the Normfinder software. Of the suitable reference miRNAs, miR-664a-3p was detected
in all samples and was used for normalization. Normalized expression values for each miRNA
in each sample were calculated using the quantification cycle (Cq) from PCR analyses and the
formula: average Cq (all samples)–assay Cq (sample).
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In situ hybridization
In order to study the cellular and subcellular location of miR-143 and miR-145 in benign and
malignant breast tissue, we analyzed the miRNA in situ hybridization (ISH) staining in full his-
tological slides of 16 tumors with adjacent normal tissue. Buffers and detection reagents were
purchased from Roche (Basel, Switzerland) and labelled locked nucleic acid (LNA) modified
probes purchased from Exiqon (Vedbaek, Denmark). The chromogen ISH was performed in
the Ventana Discovery Ultra instrument for IHC and ISH (Ventana Medical Systems Inc, Ari-
zona, USA) with deparaffinization, pretreatment, hybridization, chromogen staining and
counterstaining automatized in the instrument. In short, 4 μm tissue sections were incubated
overnight at 60˚C to attach tissue to Super Frost Plus slides. To ensure good distribution of
reagents and protect sections from drying, liquid coverslip oil (Roche) was added during incu-
bation. Sections were deparaffinized in EZ Prep buffer (Roche) at 68˚C (3 x 12 min), followed
by heat-mediated retrieval pretreatment at 95˚C with CC1 buffer (Roche) for 40 minutes and
rinsing with Reaction Buffer (Roche) followed by RiboWash SSPE buffer (Roche). In this
study, we used 5 nM miR-145-5p target probe, 10 nM miR-143-3p target probe, 10 nM scram-
ble miR negative control probe and 0.5 nM U6 positive control probe. Positive and negative
tissue controls for both miRNAs were included by using a TMA multi-organ slide.
All slides were denaturated for 8 min at 90˚C, hybridization with probes took place for 60
min at 50˚C for miR-145, 55˚C for miR-143, 57˚C for scramble miR and 55˚C for U6. Strin-
gent washes were done 2 x 8 minutes with 2.0X RiboWash SSPE, followed by rinsing with
Reaction Buffer and blocking against unspecific binding with blocking solution (Roche) for 16
minutes at 37˚C. Immunological detection was done with prediluted alkaline phosphatase
(AP)-conjugated anti-DIG (Roche) at 37˚C for 20 minutes. The sections were rinsed with
Reaction Buffer and EZ Prep before the substrate enzymatic reactions were carried out with
NBT/BCIP (CromoMap Blue kit, Roche) for 60 minutes at 37˚C. Sections were rinsed with
Reaction Buffer and counterstained for 4 minutes with Red Stain II (Roche). Dehydration of
the sections was performed by increasing gradients of ethanol and finally the tissue sections
were mounted with glass cover slips.
Scoring of ISH staining intensity. ISH stained full slides of selected tumors were used to
collect information on staining intensity and density in tumor cells, stromal fibroblast and
adjacent normal breast tissue. The tumors were randomly selected from histological slides of
good quality with well preserved invasive carcinoma present. For each slide, three areas of
tumor tissue and tumor-associated stromal tissue were evaluated using a microscope at 200x
magnification. By morphologic criteria, the tumor cells and stromal fibroblasts were scored for
staining intensity with the dominant staining intensity scored as: 0 = negative, 1 = weak,
2 = moderate, 3 = strong. From the observed ISH staining pattern, both tumor cells and stro-
mal fibroblasts stained diffusely and homogenously and hence staining density was not scored
since it did not give any additional information. All samples were independently scored by two
experienced pathologists (L.M. and S.M.D.).
Statistics
The miRNA microarray and PCR expression data from the breast cancer samples in the
NOWAC study were analyzed using the Limma package in R (Linear Models for Microarray
and RNA-Seq Data). Moderated F-statistics were applied, with p-values corrected for multiple
testing by controlling the false discovery rate using the method of Benjamini & Hochberg.
Descriptive statistics, non-parametric tests and correlation analysis were performed using
Stata, version 14.
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For the qPCR results from the in vitro experiments, the standard error was calculated using
all four technical replicates from a representative biological experiment. For the proliferation
study, each proliferation curve was tested against the miRNA control using one-way ANOVA
with p-values corrected for multiple testing by controlling the false discovery rate using the
method of Benjamini & Hochberg. For the invasion study, the standard error was calculated
using all four technical replicates from a representative biological experiment.
Results
Relative expression of miR-143 and miR-145 in breast cancer
The endogenous expression of miR-143 and miR-145 in the studied BC cell lines was quanti-
fied relative to the non-cancerous cell line MCF-10A (Fig 1). Relative to MCF-10A, endoge-
nous expression levels of miR-143 and miR-145 were downregulated in all BC cell lines. This
pattern was also evident in the NOWAC patient material, as described later.
Functional studies on miR-143 and miR-145 in vitro
The potential functional role of miR-143 and miR-145 in breast cancer tumorigenesis was
explored by a series of in vitro experiments. Proliferation and invasion were assessed after
Fig 1. MiRNA expression in breast cancer cell lines and tumor tissue relative to non-cancerous control. Endogenous expression of miR-143 and miR-
145 in breast cancer cell lines compared to the non-cancerous breast cell line MCF-10A and in breast cancer tumors compared to benign breast tissue,
analyzed using PCR or microarray technology. Data from cell lines are presented as mean log fold change ±SE from a representative biological replicate
using all four technical replicates. *** signifies P<0.001 using moderated F-statistics and the Benjamini & Hochberg correction.
https://doi.org/10.1371/journal.pone.0186658.g001
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transfecting BC cell lines with either miR-143, miR-145, or miR-143 and miR-145 in
combination.
miR-143 promotes proliferation in vitro. The proliferation rate of the BC cell lines was
assessed using the real-time monitoring system xCelligence, fitted with a proliferation plate.
Interestingly, transfection of miR-143 led to increased proliferation in the ER+ cell line MCF7
and the TN cell line MDA-MB-231 (Fig 2A and 2C). The HER2+ cell line, however, did not
demonstrate any significant change in proliferation when transfected with miR-143 (Fig 2B).
miR-145 inhibits proliferation in vitro. All three studied BC cell lines demonstrated a
dramatic drop in proliferation when transfected with miR-145 (Fig 2A–2C). The shift in prolif-
eration capacity occurred between 24–48 hours after transfection, depending on the cell line.
miR-143 and miR-145 inhibits invasion in vitro. The cells’ invasive abilities were studied
using a Boyden chamber assay. Pretransfected cells were seeded in serum-free media in the
upper chambers, and allowed to invade through a basement membrane extract towards the
bottom chamber containing media with 10% serum. Invading cells were quantified 20–24
Fig 2. Functional studies on BC cell lines after transfection with miR-143 and/or miR-145. ER+ MCF7 cells (panel A), HER2+ SK-BR-3 cells (panel B)
and triple negative MDA-MB-231 cells (panel C) were transfected with miR-143 mimic, miR-145 mimic, either alone or in combination, or with control mimic,
and cell proliferation monitored in real time using xCelligence. Data presented are representative for all three biological replicates, and include four technical
replicates for each transfection. *** signifies P<0.001 using one-way ANOVA and the Benjamini & Hochberg correction comparing miR-143 and/or miR-145
transfected cells to controls. The invasion capacity (panel D) of all BC cell lines transfected with either miR-143, miR-145, or miR-143 and miR-145, was
studied using the CytoSelect Cell Invasion Assay with chambers separated by a basement membrane. Results are presented as mean log fold change ± SE
of transfected cells relative to negative controls from a representative biological experiment with four technical replicates for each cell line.
https://doi.org/10.1371/journal.pone.0186658.g002
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hours after being seeded to the upper chamber. Both miR-143 and miR-145 had a profound
effect on cell invasion (Fig 2D). All cell lines demonstrated reduced invasive capacity 24 hours
after transfection.
Cotransfection of miR-143 and miR-145 results in a tumor suppressor phenotype. In
addition to investigating the functional effects of each individual miRNA, we also wanted to
study the effects of cotransfecting miR-143 and miR-145. The BC cell lines were simulta-
neously transfected with 50 nM of both miR-143 and miR-145. The proliferation of cells
cotransfected with miR-143 and miR-145 was dramatically reduced in all three cell lines and
was similar to the proliferation pattern of cells transfected with miR-145 alone (Fig 2A–2C).
The proliferation promoting effects observed for miR-143 in the ER+ cell line and the TN cell
line were cancelled by the simultaneous transfection of miR-145 (Fig 2A and 2C). Cotransfec-
tion of miR-143 and miR-145 had an inhibitory effect on invasion, in line with the observa-
tions made for each individual miRNA (Fig 2D). The cumulative effect of cotransfection using
both miRNAs was not significantly different from experiments where only one miRNA was
used.
Patient material
A total of 108 NOWAC postgenome cohort participants were diagnosed with BC at the pathol-
ogy departments in Northern Norway in the years 2004–2010 and included in the study. Of
these, one case had no FFPE tissue block with enough tumor tissue for further analyses. Five
cases and six of the benign tissue controls had poor RNA quality, leaving 102 BC surgery speci-
mens and 38 of the 44 benign breast specimens to be included in the miRNA microarray.
After microarray miRNA analyses, an additional case and two of the controls were identified
as outliers and excluded from further statistical analyses. The histopathological variables for
the study cohort are presented in Table 1.
Expression of miR-143 and miR-145 in benign and malignant breast
tissue and according to histopathological parameters: microarray and
PCR-results
Microarray miRNA analyses demonstrated that miR-143 and miR-145 were significantly
downregulated in BC tissue compared to benign breast tissue (p<0.001 for both comparisons)
and the downregulation was validated and confirmed by PCR (p<0.001) (Fig 1). Of note,
microarray- and PCR-based expression levels were significantly correlated for both miR-143
(r = 0.60, p<0.001) and miR-145 (r = 0.72, p<0.001). Additionally, the expression levels of
miR-143 and miR-145 were highly correlated (R = 0.88, p<0.001, Fig 3).
Based on PCR measurements, both miR-143 and miR-145 demonstrated significantly
higher expression in tumors that typically have a better prognosis compared to the rest. There
was higher expression of both miR-143 and miR-145 in low and intermediate grade tumors
compared to the high grade tumors, as shown in Tables 2 and 3 and Fig 4, and in ER-positive
compared to ER-negative tumors (Table 4). MiR-145 displayed higher expression in luminal A
tumors compared to the other molecular subtypes, and the expression of both miRNAs was
lower in basal-like tumors compared to the other major subtypes (Table 5 and Fig 5). The
means plot for miR-143 and miR-145 in Fig 6A and 6B, respectively, illustrates the distribution
of expression across molecular subtypes. The same trends were observed in the microarray
results, but the differences were not statistically significant. There were no significant differ-
ences in miR-143 and miR-145 expression between tumor groups stratified according to
tumor size or lymph node metastases.
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ISH expression of miR-143 and miR-145 in benign and malignant breast
tissue
The cellular and subcellular expression of miR-143 and miR-145 in benign and malignant
breast tissue was evaluated in full histological slides of 16 tumors with adjacent benign breast
tissue. MiR-143 ISH staining was mainly cytoplasmatic and found predominantly in luminal
cells in benign breast tissue. Noteworthy, the staining intensity in benign breast ducts and
lobuli was strong and homogenous, and appeared stronger in benign tissue compared to adja-
cent tumor tissue, also in the tumors with moderate to strong staining intensity (Fig 7). As in
benign tissue, miR-143 was expressed in the cytoplasm of tumor cells and stromal fibroblasts.
However, in the tumors with high staining intensity in stromal cells, the staining was both
cytoplasmatic and nuclear.
In contrast to the cytoplasmatic staining pattern for miR-143, miR-145 was expressed in the
nuclei and with the strongest staining intensity in the myoepithelial cells in benign breast tis-
sue (Fig 7). MiR-145 staining intensity was strong in benign breast tissue and tended to be
stronger in benign compared to malignant breast tissue, but the difference was not as clear as
for miR-143 (Fig 7). Also in tumor cells and stromal fibroblasts, miR-145 staining was pre-
dominantly nuclear.
Tumor cells and stromal fibroblasts were scored for staining intensity as illustrated in Fig 8.
Noteworthy, all 16 tumors had positive staining for both miR-143 and miR-145 in both tumor
cells and fibroblasts. The mean staining intensity for miR-143 in tumor cells was 2.17 and in
stromal fibroblasts 2.06 whereas mean miR-145 staining intensity was 2.10 in tumor cells and
1.69 in stromal fibroblasts. Using Spearman’s rho, the staining intensity in tumor cells and
Table 1. Histopathological variables for the breast cancer cases included in the study.
NOWAC study
Variables N (%)
Study subjects All 108 (100)
Tumor size 10 mm 23 (21.3)
11–20 mm 50 (46.3)
>20 mm 34 (31.5)
Unknown 1 (0.9)









Lymph node met No 73 (67.6)
Yes 34 (31.5)
Unknown 1 (0.9)
Molecular subtype Luminal A 58 (53.7)
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stromal fibroblasts was found to be positively correlated for both miR-143 (p = 0.006) and
miR-145 (p = 0.006). Stromal ISH expression of miR-143 and miR-145 was also correlated
(p = 0.049) (Table 6).
Discussion
This study characterizes the functional properties and expression pattern of the miRNA cluster
miR-143 and miR-145 in BC.
Using microarray and PCR, we found a significant downregulation of miR-143 and miR-
145 in malignant tumors compared to normal tissue, which is in line with previously published
studies in breast cancer [29–31] and other tissues, especially colorectal carcinomas [32]. How-
ever, in our study the results were also verified by ISH, which added interesting data on the cel-
lular and subcellular location of these miRNAs in benign and malignant breast tissue. Using
ISH, we found the highest expression of miR-145 in myoepithelial cells in benign breast tissue.
This is in line with other smaller studies using FISH or laser microdissection and PCR-analyses
of miRNA expression [33, 34]. Further, we observed a distinct nuclear enrichment of mature
miR-145, as has been previously reported in both breast and other tissues [34–36]. This is
interesting, as the general dogma of miRNA biosynthesis and function involves post-
Fig 3. Scatterplot of miR-143 and miR-145 expression in breast tumor tissue. Scatterplot of miR-143 and miR-145 expression
in tumor tissue, measured by PCR. Spearman’s rho (R) is presented in the figure (***P<0.001).
https://doi.org/10.1371/journal.pone.0186658.g003
Study of the miR-143/145 cluster in breast cancer
PLOS ONE | https://doi.org/10.1371/journal.pone.0186658 October 26, 2017 11 / 22
transcriptional regulation of mRNA in the cytoplasm [37]. Although the nuclear functions of
mature miRNAs remain elusive, there is growing evidence of specific miRNAs localized to the
nucleus [38–40]. Park et al. suggest that nuclear miRNAs could uncover an entirely new role
for this family of non-coding RNAs [40] where transportation across the nuclear membrane
could regulate miRNA storage and function. Further, it is suggested that nuclear miRNA
could be involved in post-transcriptional gene silencing via the nuclear RNA induced silencing
complex (nRISC), transcriptional gene activation via recruitment of transcriptional activators,
and influence splicing decisions at specific exons (alternative splicing) [41].
Using microarray and PCR, we found miR-145 to be significantly higher in ER+ tumors,
which is in line with a previous study on lymph-node negative tumors where ER status was
based on gene expression using microarray [42]. In our study, the expression of both miR-143
and miR-145 was elevated in the least aggressive tumor types, which is in line with the tumor
suppressor functions described for these miRNAs in previous publications [15–19, 43]. Fur-
ther, the expression of the two miRNAs seems to correlate in benign and malignant breast tis-
sue and between tumor types, an observation that could partly be contributed to their
Table 2. Descriptive data for miR-143 and miR-145 PCR measurements in breast tumors according to
histological grade.
Tumor grade miR-143 miR-145
Control Mean 4.18 5.98
SD 0.81 0.69
N (%) 19 (100) 19 (100)
All cancers Mean 2.82 3.32
SD 1.16 1.53
N (%) 40 (100) 40 (100)
Tumor grade 1 Mean 2.77 3.40
SD 1.07 1.21
N (%) 7 (17.5) 7 (17.5)
Tumor grade 2 Mean 3.21 3.92
SD 0.85 1.05
N (%) 17 (42.5) 17 (42.5)
Tumor grade 3 Mean 2.47 2.62
SD 1.41 1.84
N (%) 16 (40) 16 (40)
https://doi.org/10.1371/journal.pone.0186658.t002
Table 3. Contrast tests of miR-143 and miR-145 PCR measurements in breast tumors according to
histological grade.
miRNA Test Mean difference P*
miR-143 Control vs cancer 1.36 <0.001
Grade 1 vs 2 and 3 -0.07 0.88
Grade 1 and 2 vs 3 0.52 0.17
Grade 1 vs 3 0.30 0.56
miR-145 Control vs cancer 2.66 <0.001
Grade 1 vs 2 and 3 0.13 0.82
Grade 1 and 2 vs 3 1.04 0.03
Grade 1 vs 3 0.78 0.23
*False discovery rate (FDR) adjusted P-value
https://doi.org/10.1371/journal.pone.0186658.t003
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transcriptional regulation, where the two miRNAs are located within the same chromosomal
region and are transcribed as a cluster.
However, miRNA functions are complex. In our in vitro experiments, miR-143 was
revealed to increase the proliferative capacity of the ER+ cell line MCF7 and the TN cell line
MDA-MB-231, whilst having no significant effect on proliferation in the HER2+ cell line
SK-BR-3. The effect was pronounced (Fig 2A and 2C), and reproduced in three biological rep-
licates. This finding is in contrast to the majority of studies regarding the effect of miR-143 on
proliferation [15–19]. Interestingly, we found that miR-143 had a significant inhibitory effect
on cell invasion in all cell lines. The overexpression of miR-145 led to inhibition of both prolif-
eration and invasion, which is in accordance with the general consensus [19, 20, 22–24, 44–
51]. Noteworthy, the coexpression of miR-143 and miR-145 led to inhibition of proliferation
and invasion, which is also described in previous publications [52–55]. At present, we do not
have enough information to offer any explanatory model for the effects demonstrated by miR-
Fig 4. MiRNA expression in tumor tissue, stratified according to histological grade. Mean differences ±SD in miRNA expression in tumor versus benign
breast tissue and between tumors stratified according to histological grade, are presented. Statistics are calculated using one-way ANOVA with p-values
corrected for multiple testing (*P<0.05, ***P<0.001).
https://doi.org/10.1371/journal.pone.0186658.g004






miR-143 3.18 2.37 0.81 0.02
miR-145 3.89 2.52 1.37 <0.001
*FDR adjusted P-value
https://doi.org/10.1371/journal.pone.0186658.t004
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143 in our proliferation studies. However, Dimitrova et al. describe stromal expression of the
miR-143/145 cluster as a stimulator of neoangiogenesis, and a supporter of tumor expansion
in lung [56]. Recently, Donnarumma et al. reported that the levels of miR-143 are increased in
exosomes from cancer associated fibroblasts, and could promote breast cancer progression
Table 5. Contrast tests of miR-143 and miR-145 PCR measurements in breast tumors according to
molecular subtype.
miRNA Test Mean difference P*
miR-143 Control vs cancer 1.36 <0.001
Luminal A vs others 0.61 0.13
Luminal B vs others 0.37 0.36
HER2+ vs others 0.08 0.88
Basal-like vs others -1.06 0.01
miR-145 Control vs cancer 2.66 <0.001
Luminal A vs others 1.02 0.02
Luminal B vs others 0.66 0.11
HER2+ vs others -0.03 0.96
Basal-like vs others -1.65 <0.001
*FDR adjusted P-value
https://doi.org/10.1371/journal.pone.0186658.t005
Fig 5. MiRNA expression in tumor tissue, stratified according to molecular subtype. Mean differences ±SD in miRNA expression between tumors
stratified according to molecular subtype are presented. Statistics are calculated using one-way ANOVA with p-values corrected for multiple testing.
(*P<0.05, **P<0.01, ***P<0.001).
https://doi.org/10.1371/journal.pone.0186658.g005
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through exosome-mediated delivery of miRNA to breast cancer cells [57]. Estradiol has been
published to downregulate expression of miR-143 in an ER-dependent manner in the ER+ cell
line MCF7, whilst having no effect on miRNA levels in the TN cell line MDA-MB-231 [43].
Downregulation of miR-143 appears to contribute to the estradiol-mediated upregulation of
bcl-2 and survivin. These observations underline that effects of signaling molecules, where
miRNAs could be included, are highly dependent on the cellular context. Further, the stimula-
tion of proliferation and, at the same time, inhibition of invasion, argue for several regulated
target genes which could have opposing effects in tumorigenesis, as indeed demonstrated by
the target genes for miR-143 listed in S1 Table.
Spizzo et al. verified miR-145 to directly target ER, and at the same time activate TP53, and
in turn apoptosis [51]. These results may in part explain some of the inhibitory effects we
Fig 6. Means plot of miR-143 and miR-145 in breast tumors according to molecular subtype. Means plot
for the expression of miR-143 (panel A) and miR-145 (panel B) according to molecular subgroup, using PCR.
Error bars describe the standard error in each subgroup.
https://doi.org/10.1371/journal.pone.0186658.g006
Fig 7. MiR-143 and miR-145 in situ hybridization staining pattern in breast tissue. Illustrative examples of miR-143 and miR-145 in situ hybridization
staining pattern in benign breast tissue (x400 magnification) and adjacent benign and malignant breast tissue (x200 magnification).
https://doi.org/10.1371/journal.pone.0186658.g007
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observed in cell lines transfected with miR-145, but our experiments also demonstrated inhibi-
tion of proliferation and invasion in the TN p53 mutant MDA-MB-231 and the ER- p53
mutant SK-BR-3. These results argue for a different tumor suppressive pathway than described
by Spizzo et al. However, the list of verified miR-145 target genes involved in tumor
Fig 8. MiR-143 and miR-145 in situ hybridization staining intensities in tumor and stromal cells. In situ hybridization staining of miR-143 and miR-145
in tumor cells (panel A-C and panel D-F, respectively) and stromal fibroblasts (panel G-I and panel J-L, respectively) with examples of staining intensities
corresponding to score weak, moderate and strong. Light microscope images, x400 magnification.
https://doi.org/10.1371/journal.pone.0186658.g008
Table 6. Correlations of miR-143 and miR-145 in situ hybridization staining intensities in tumor and stromal cells.
N = 16 miR-143 miR-145
Tumor Stroma Tumor Stroma
miR-143 Tumor r 0.657** 0.335 0.411
Stroma r 0.657** 0.275 0.499*
miR-145 Tumor r 0.335 0.275 0.651**
Stroma r 0.411 0.499* 0.651**
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progression is wide-ranging (S2 Table), and the dominant active pathway(s) at any given time
would be challenging to predict. S1 and S2 Tables present the validated mRNA targets for
miR-143 and miR-145, based on searches using the online database miRTarBase [58].
Synergistic effects of miR-143 and miR-145 on BC cell proliferation have been demon-
strated in MCF7 and MBA-MD-231 cells and in a mouse model using MCF7 xenografts [53].
Interestingly, both miRNAs, although not sharing sequence homology, were demonstrated to
bind to the 3’-UTR region of HER3, the most potent effects were demonstrated by miR-145.
Further, high HER3 expression could rescue the cells from the inhibitory effects of miR-143
and miR-145, underlining the importance of the cellular context and active signaling pathways
on the net effect of miRNA up- or downregulation. Different results in different cell lines may
be explained by miRNAs effects on target genes that are operating or driving the oncogenic
phenotype in specific cell types where ER would be the classical example in ER+ BC. Notewor-
thy, miRNA-profiling of BC cells has demonstrated that miRNA-based clusters follow ER-
based dichotomization of cell lines, indicating that a significant number of miRNAs may
directly, or indirectly, be regulated by ER-signaling [59].
The results in this study, including the differential effects in vitro of miR-143 in BC cell lines,
the effects of cotransfecting miR-143 and miR-145, and the nuclear enrichment of miR-145 in
breast tissue, underline the complexity of miRNA regulation and function. Studies of miRNA
expression in tissues and cancer types should be supplied by functional research of individual
miRNAs where non-canonical effects of miRNAs are being explored in greater detail.
Supporting information
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